Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Mr. Daniel J. O'Connell M.B.A. |
IPO Date | July 1, 2021 |
Location | United States |
Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
Employees | 51 |
Sector | Healthcare |
Industry | Biotechnology |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
NA
StockViz Staff
September 19, 2024
Any question? Send us an email